Dorgan, McCain, Snowe introduce bill to allow prescription drug reimportation

Sens. Byron Dorgan (D-N.D.), John McCain (R-Ariz.) and Olympia Snowe (R-Maine) on Wednesday introduced a bill (S 525) that would allow the reimportation of lower-cost prescription drugs from other nations, Bloomberg reports.

The lawmakers said that the legislation would save the U.S. $50 billion, which includes $10 billion in savings for the U.S. government, over the next 10 years. According to a statement from the lawmakers, the legislation would "bring consumers immediate relief and will ultimately force the pharmaceutical industry to lower drug prices in the U.S." Julia Wanzco, a spokesperson for Snowe, said, "We do expect this to pass" in part because President Obama in his fiscal year 2010 budget proposal announced a "strong interest in implementing this policy."

The Pharmaceutical Research and Manufacturers of America opposes the legislation because of safety concerns. In a statement, Ken Johnson, senior vice president at PhRMA, said, "The worldwide counterfeit threat is knocking at America's door and will soon be greeted if prescription drug importation moves forward," adding, "Interest in prescription drug importation is waning in part due to the millions of seniors accessing medicines and saving money through the Medicare prescription drug program and consumer weariness in the aftermath of recalled tainted foreign products" (Randall, Bloomberg, 3/4).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Neuroactive drugs show promising anti-glioblastoma effects in preclinical trials